HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

docetaxel (Taxotere)

semisynthetic analog of taxol; structure given in first source; RN given refers to anhydrous compound; 148408-66-6 is the isomer (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))

Also Known As:

Taxotere; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; NSC 628503; RP 56976; RP-56976; Taxoltere metro; docetaxel, isomer; docetaxol; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

Networked: 7054 relevant articles (1203 outcomes, 2849 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Terpenes: 260
    - Diterpenes: 237
      - Taxoids: 1654
        docetaxel: 7054
  - Cyclic Hydrocarbons: 3
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 5
        Cyclodecanes
        Taxoids: 1654
        docetaxel: 7054

Experts

1.	Beer, Tomasz M: 46 articles (11/2015 - 01/2002)
2.	Georgoulias, V: 41 articles (07/2015 - 01/2000)
3.	Petrylak, Daniel P: 35 articles (12/2015 - 08/2002)
4.	Carducci, Michael A: 32 articles (04/2015 - 03/2002)
5.	Armstrong, Andrew J: 28 articles (10/2015 - 04/2005)
6.	Georgoulias, Vassilis: 28 articles (08/2015 - 04/2002)
7.	Fizazi, Karim: 27 articles (01/2016 - 09/2004)
8.	Figg, William D: 27 articles (01/2014 - 01/2003)
9.	Dreicer, Robert: 26 articles (08/2015 - 01/2003)
10.	Oudard, Stéphane: 26 articles (07/2015 - 05/2005)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 07/01/2002 - "Docetaxel has proven efficacy in metastatic breast cancer. " 04/01/2000 - "Docetaxel has proven effective in advanced breast cancer. " 01/01/2005 - "High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer." 06/01/2002 - "The consistent demonstration of a high level of efficacy with manageable toxicity ensures the continued widespread investigation of docetaxel in metastatic breast cancer." 11/01/2008 - "At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role."
2.	Prostatic Neoplasms (Prostate Cancer) 03/01/2014 - "Our findings, obtained with a highly clinically relevant prostate cancer model, suggest, for the first time, that docetaxel-based therapy of advanced human prostate cancer may be improved by combining docetaxel with Aneustat." 03/19/2013 - "Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1." 09/15/2010 - "Docetaxel is one of the few chemotherapeutic drugs that are considered highly effective when used to treat prostate cancer patients that have relapsed and/or metastatic disease, it is therefore reasonable to expect further improvements in treatment outcomes when it is combined with other therapeutic agents active in prostate cancer. " 11/01/2014 - "Although docetaxel is still considered a mainstay of treatment in metastatic castrate-resistant prostate cancer (mCRPC), in the last few years, new agents have been developed to improve survival in this setting and reach a possible optimal personalized treatment strategy. " 12/01/2009 - "The finding of improved overall survival has significant implications since no therapy to date, except for docetaxel-based regimens, has been shown to improve overall survival in metastatic prostate cancer. "
3.	Neoplasms (Cancer) 03/18/2015 - "By contrast, selectively inhibiting BCL-XL did not suppress granulopoiesis but was highly efficacious in combination with docetaxel when tested against a range of solid tumors. " 03/01/2001 - "Docetaxel delayed tumor growth and enhanced the efficacy of radiation: it dramatically reduced TCD50 (radiation dose yielding 50% tumor cure) from the control value of 38.6 Gy to 11.8 Gy, for an enhancement factor of 3.27. " 04/01/2013 - "We designed a risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with cancer in order to determine the optimal dose according to age, comorbidity and functional status. " 01/01/2014 - "Anti-tumor efficacy of the PS-PDLLA/DCT NPs in PC-3 cells was significantly more potent than that of the group treated with commercially available DCT, Taxotere (P<0.05). " 06/01/2013 - "The ability to deliver the potent anti-cancer agent docetaxel via the oral route may enable the development of promising new treatment regimens with reduced toxicity, increased efficacy, and increased patient convenience. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/01/1999 - "Results of a multicenter phase III trial of docetaxel versus best supportive care for the first-line treatment of non-small cell lung cancer are pending. " 01/01/2003 - "The cytotoxic agent docetaxel not only has proven activity in non-small cell lung cancer-when used alone or in combination-but is also a potent radiosensitizer, and improved treatments are needed in all stages of this disease. " 10/01/2007 - "According to this meta-analysis, docetaxel is superior to vinca alkaloid-based regimens in terms of OS and safety for first-line therapy of advanced non-small cell lung cancer." 12/01/2009 - "To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC. " 09/01/2004 - "Although the validity of the results of this study is limited due to the small sample size, docetaxel appears effective in selected elderly patients with advanced non-small-cell lung cancer."
5.	Stomach Neoplasms (Stomach Cancer) 02/01/2014 - "As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. " 02/01/2014 - "The combination of docetaxel and S-1 (DS) therapy is effective in patients with unresectable gastric cancer and is expected to be a regimen in neoadjuvant setting for advanced gastric cancer. " 01/01/2013 - "Therefore, Plu-CLA is a potential intraperitoneal-route carrier for hydrophobic docetaxel for the effective treatment of peritoneal metastatic gastric cancer." 01/01/2005 - "The combination of docetaxel and capectabine was found to be well tolerated and effective in patients with advanced gastric cancer. " 04/01/2012 - "Our study, for the first time, rationally demonstrated that LDM docetaxel treatment used alone or combined with EGCG is effective and safe in preclinical settings of gastric cancer. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	docetaxel (Taxotere)
3.	gemcitabine
4.	Paclitaxel (Taxol)
5.	Fluorouracil (Carac)
6.	Hormones
7.	capecitabine (Xeloda)
8.	Carboplatin (JM8)
9.	trastuzumab (Herceptin)
10.	Doxorubicin (Adriamycin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Castration
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Radiotherapy